STACY GRIFFIN: Open Payments
NPI 1245952530 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$370 in 22 payments from 9 companies in 2025. Trend: 2023 $710 · 2024 $508 · 2025 $370
Food & beverage: $287Education: $83
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 11 | $141 |
| Axsome Therapeutics, Inc. | 3 | $68 |
| Janssen Pharmaceuticals, Inc | 2 | $44 |
| ABBVIE INC. | 1 | $29 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Corium, LLC | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $15 |
Products named: FANAPT, Auvelity, SPRAVATO, VRAYLAR, REXULTI, Azstarys, TRINTELLIX, Qelbree.
Industry payments across IN — which companies pay providers there.
